Differential regulation patterns of the anti‐CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|168|4|606-610

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.168, Iss.4, 2015-02, pp. : 606-610

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

By Dillman R.  

Clinical and Experimental Medicine, Vol. 6, Iss. 1, 2006-03 ,pp. : 1-12

Springer Publishing Company

Access to resources Recommend Favorite

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

By  

Case Reports in Oncology, Vol. 2, Iss. 3, 2009-10 ,pp. : 194-202

Karger

Access to resources Recommend Favorite

Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the Literature

By  

Oncology Research and Treatment, Vol. 26, Iss. 4, 2003-09 ,pp. : 351-354

Karger

Access to resources Recommend Favorite

Anti-CD20 Monoclonal Antibody (Rituximab) and Cidofovir as Successful Treatment of an EBV-Associated Lymphoma with CNS Involvement

By  

Oncology Research and Treatment, Vol. 24, Iss. 5, 2001-10 ,pp. : 491-494

Karger

Access to resources Recommend Favorite

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody‐dependent cytotoxicity and improves overall survival against CD20+ rituximab‐sensitive/‐resistant Burkitt lymphoma (BL) and precursor B‐acute lymphoblastic leukaemia (pre‐B‐ALL): potential targeted therapy in patients with poor risk CD20+BL and pre‐B‐ALL

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 5, 2015-12 ,pp. : 763-775

John Wiley & Sons Inc

Access to resources Recommend Favorite